Taysha Gene Therapies, Inc.

TSHA Nasdaq CIK: 0001806310

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 3000 PEGASUS PARK DRIVE, DALLAS, TX, 75247
Mailing Address 3000 PEGASUS PARK DRIVE, DALLAS, TX, 75247
Phone (214) 612-0000
Fiscal Year End 1231
EIN 843199512

Financial Overview

FY2025 FY

$9.77M
Revenue
-$89.30M
Net Income
$96.38M
Total Liabilities

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events March 19, 2026 View on SEC
10-K Annual financial report March 19, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 17, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) February 17, 2026 View on SEC
4 Insider stock transaction report February 6, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 5, 2026 View on SEC
4 Insider stock transaction report January 27, 2026 View on SEC
4 Insider stock transaction report January 27, 2026 View on SEC
4 Insider stock transaction report January 27, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment January 21, 2026 View on SEC

Annual Reports

10-K March 19, 2026
  • Strategic partnerships, such as with Astellas, provide funding, resources, and shared development costs without diluting ownership.
  • Active fundraising through selling new shares and private investments secures capital for costly clinical trials and gene therapy research.
View Analysis

Insider Trading

STRONG SELL 3 insiders 10 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.